相似文献
1
Ensuring transparency: presenting the trade-offs between the research treatment options.
Am J Bioeth. 2013;13(12):50-2. doi: 10.1080/15265161.2013.852272.
2
What are reasonably foreseeable risks?
Am J Bioeth. 2013;13(12):29-30. doi: 10.1080/15265161.2013.849304.
3
The weird divergence of ethics and regulation with regard to informed consent.
Am J Bioeth. 2013;13(12):31-3. doi: 10.1080/15265161.2013.849308.
4
Randomization should be disclosed to potential research subjects.
Am J Bioeth. 2013;13(12):35-7. doi: 10.1080/15265161.2013.849307.
5
Risk, respect for persons, and informed consent in comparative effectiveness research.
Am J Bioeth. 2013;13(12):46-8. doi: 10.1080/15265161.2013.851299.
6
The "research misconception" and the SUPPORT trial: toward evidence-based consensus.
Am J Bioeth. 2013;13(12):48-50. doi: 10.1080/15265161.2013.851297.
7
What should be disclosed to research participants?
Am J Bioeth. 2013;13(12):3-8. doi: 10.1080/15265161.2013.851578.
8
Randomization and the transactional framework for informed consent.
Am J Bioeth. 2009 Feb;9(2):16-7. doi: 10.1080/15265160802666297.
9
Understanding randomization: helpful strategies.
Am J Bioeth. 2009 Feb;9(2):14-5. doi: 10.1080/15265160802663245.
10
Randomization can be risky.
Am J Bioeth. 2009 Feb;9(2):17-8. doi: 10.1080/15265160802668954.
Zotero 插件